Bosutinib, also known as SKI-606, is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype. Bosutinib was approved in 2012

TM 5275 sodium salt is an orally bioavailable plasminogen activator inhibitor-1 (PAI-1) inhibitor.

A33903 is a 1,4-benzodiazepine analog that is being studied as a potential inhibitor of respiratory syncytial virus. This molecule was moderately active and demonstrated good pharmacokinetic properties.

Vaneprim is an antibacterial agent.

HM43239 is an orally active small molecule inhibitor of FLT3 that selectively inhibits not only FLT3 wild type, ITD mutants or TKD mutations, but also FLT3 ITD/TKD double mutations. HM43239 directly inhibits the kinase activity of FLT3 as a reversible Type I inhibitor and effectively modulates downstream p-STAT5 and p-ERK. HM43239 also demonstrated inhibition of SYK, JAK1/2 and TAK1, known to be involved in tumor cell proliferation and/or differentiation HM43239 monotherapy induced dose-dependent regression of tumor growth in FLT3 wild-type and FLT3 mutated leukemia cancer cell line.

NU-3, also known as Bisphosphocin NU-3, is a protonated modified nucleotide with antimicrobial activity. Nu-3 had a wide antibacterial spectrum to Gram-positive, Gram-negative and some resistant bacteria. The MIC values of Nu-3 against all tested MRSA and MSSA were roughly in a same range while MICs of Oxacillin and Vancomycin varied between the bacteria tested. In the mouse model of skin wound infection study, the treatment with 5% Nu-3 glycerine solution also showed comparable therapeutic effects to Ciprofloxacin Hydrochloride Ointment. Nu-3 represents a new class of antibacterial agents for treating topical infections and acts via a different mechanism from conventional antibiotics.

Batanopride is an antiemetic 5-HT3 receptor antagonist.

BU-226 is a Potent, highly selective I2 ligand.

OG 488 SE is a Green fluorescent dye; supplied as NHS ester. OG-488 SE is a potential fluorescein precursor for live bacteria detection.

Adekalant, also known as H 345/52. is a new antiarrhythmic compound with low proarrhythmic activity. Adekalant concentration-dependently blocked HERG-carried currents with an IC50 of 230 nM. Adekalant preferentially bound to the open channel with unusually rapid kinetics and was trapped by channel closure. Voltage-independent behavior of Adekalant was observed during both square-pulse and action potential clamp protocols. It is proposed that block of I(Kr) is the principal mechanism by which Adekalant delays repolarization in human myocardium. Adekalant blocks I(Kr) with high potency and I(Ca) with somewhat lower potency and was found to delay ventricular repolarization without substantially increasing temporal or spatial dispersion and without inducing early after-depolarizations or TdP.

Bromofosfamide, alkso known KM-135, is an alkylating agent with antitumor activity.

BMS-223131 is a novel opener of large conductance Ca2+-activated K+ (maxi-K) channels. BMS-223131 effectively reduced stress-induced colonic motility and visceral nociception supporting the potential utility of maxi-K channel openers for the treatment of bowel disorders involving dysfunctional motility and visceral sensitivity.

Bimakalim, an ATP-sensitive potassium channel opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release, and neutrophil function in dogs

Cefovecin, also known as UK-287074, is an antibiotic of the cephalosporin class. Cefovecin interferes with the synthesis of bacterial cell walls, by binding to penicillin binding proteins. Due to high protein-binding, it is not effective against species of Pseudomonas or Enterococcus. The maximum anti-bacterial activity occurs approximately two days after cefovecin has been administered. It is used to treat skin infections caused by Pasteurella multocida in cats, and Staphylococcus intermedius and Streptococcus canis in dogs.

Atibeprone, also known as Lu 53439, is MAO-B inhibitor. The anticonvulsant activity of inhibitors of monoamine oxidase (MAO) was reported early after the development of irreversible MAO inhibitors such as tranylcypromine, but was never clinically used because of the adverse effects of these compounds. In contrast to esuprone and L-deprenyl, the selective MAO-B inhibitor LU 53439 was not effective in the kindling model; this substantiates the previous notion that the anticonvulsant activity of L-deprenyl is not related to MAO-B inhibition, but to other effects of this drug, such as inhibition of MAO-A.

Naftifine is an allylamine antifungal drug for the topical treatment of tinea pedis, tinea cruris, and tinea corporis (fungal infections). Its precise mechanism of action is unknown, but may involve selectively blocking sterol biosynthesis via inhibition of the squalene 2,3-epoxidase enzyme. The half-life is approximately 2–3 days. The metabolites are excreted in the urine and feces.

Bemoradan, also known as WJ-22867, is a potent, long-acting orally active inodilator and cardiotonic agent. Bemoradan is a novel, potent positive inotropic agent, demonstrated biphasic inhibition of the fraction III enzyme from canine cardiac muscle. Bemoradan is well and rapidly absorbed after oral dosing, has linear pharmacokinetics and long elimination half-lives across species.

WAY-117885 is a laboratory reagent, which may be used for altering the lifespan of a eukaryotic organism.

BMS-363131 is very potent inhibitor of human tryptase with high selectivity versus other serine proteases, including trypsin.

WAY-638394 is a laboratory reagent, which may be useful for treating bone deficit conditions.

WAY-348941 is an immunosuppressive agent.

WYE-176182 is an apical sodium-dependent bile salt transporter (SLC10A2) inhibitor

WAY-300716 is a useful chemical reagent for laboratory study.

PFSM-B5, also known as DUN 00302.

PF-CBP1, also known as PF-06670910, is potent and highly-selective inhibitor of the bromodomain of CREB binding protein (CBP BRD) that down regulates targets of CBP in macrophages primary neurons.

TMPH is an inhibitor of CNS nicotinic receptor. Evaluation of nicotinic acetylcholine receptor (nAChR) subunits expressed in Xenopus laevis oocytes indicated that TMPH can produce a potent and long-lasting inhibition of neuronal nAChR formed by the pairwise combination of the most abundant neuronal α (i.e., α3 and α4) and β subunits (β2 and β4), with relatively little effect, because of rapid reversibility of inhibition, on muscle-type (α1β1γδ) or α7 receptors.

Deuremidevir, also known as VV116, JT001, and mindeudesivir, is a chemically-modified version of the antiviral remdesivir with oral bioavailability and potent activity against SARS-CoV-2. Deuremidevir is a deuterated, tri-isobutyrate ester prodrug of the RDV parent nucleoside, and is rapidly metabolized into the parent nucleoside (116-N1) in the body. 116-N1 is intracellularly converted to the nucleoside triphosphate active form, which would interfere with the function of RNA-dependent RNA polymerase of SARS-CoV-2, thus exerting antiviral effects. Deuremidevir showed potent activity against a panel of SARS-CoV-2 variants (alpha, beta, delta, and omicron) and excellent therapeutic efficacy in the mice model. Note: the non-labeled analog is called GS621763 (Cat#465727).

ABT-925, also known as A-37203, BSF-201640; DAT-201; Lu-201640; and A-437203, is a selective dopamine D3 receptor (DRD3) antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors. ABT-925 was tested in schizophrenia. ABT-925 is a selective dopamine D₃ receptor antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors.

W-9 is a Calmodulin antagonist

NAN-190 is a mixed antagonist and partial agonist of the serotonin (5-HT) receptor subtype 5-HT1A. NAN-190 potentiates the circadian response to light and speeds re-entrainment to advanced light cycles. NAN-190 potentiates the impairment of retention produced by swim stress. NAN-190 is a possible antagonist for methamphetamine.